Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terutroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 8/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 11/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terutroban SCHEMBL1896773 | 1.00 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL29378918 | 1.00 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL29522952 | 0.91 | TBXA2R (0.84) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9252158 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9247892 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1 | |
| SCHEMBL12675846 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9015506 | 0.89 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9246542 | 0.89 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9247825 | 0.88 | TBXA2R (0.78) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7771697 | 0.87 | TBXA2R (0.78) | TBXA2RTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155195-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| EP-1842537-B1 | Use of an anti-atherothrombotic compound for the manufacture of medicaments for the treatment of cerebrovascular disorders | SERVIER LAB (FR) | 2009-12-23 | — | — | EP | claimed |
| EP-2098511-A1 | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring | Solvias AG (CH) | 2009-09-09 | — | — | EP | claimed |
| WO-2008127682-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | claimed |
| US-20070238785-A1 | Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders | LES LABORATOIRES SERVIER (FR) | 2007-10-11 | — | — | US | claimed |
| EP-0648741-B1 | 1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents | ADIR (FR) | 1996-12-18 | — | — | EP | claimed |
| US-5472979-A | Antithrombotics | ADIR ET COMPAGNIE (FR) | 1995-12-05 | — | — | US | claimed |
| US-12446907-B2 | Methods and apparatus for flow restoration | COVIDIEN LP (US) | 2025-10-21 | — | — | US | disclosed |
| US-20230338048-A9 | METHODS AND APPARATUS FOR FLOW RESTORATION | COVIDIEN LP | 2023-10-26 | — | — | US | disclosed |
| US-20230079665-A1 | METHODS AND APPARATUS FOR FLOW RESTORATION | COVIDIEN LP (US) | 2023-03-16 | — | — | US | disclosed |
| US-11529156-B2 | Methods and apparatus for flow restoration | COVIDIEN LP (US) | 2022-12-20 | — | — | US | disclosed |
| US-20190350604-A1 | METHODS AND APPARATUS FOR FLOW RESTORATION | MICRO THERAPEUTICS, INC. | 2019-11-21 | — | — | US | disclosed |
| US-10456151-B2 | Methods and apparatus for flow restoration | COVIDIEN LP (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2008127682-A2 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070238785-A1 | Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders | LES LABORATOIRES SERVIER (FR) | 2007-10-11 | — | — | US | disclosed |
| EP-0648741-B1 | 1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents | ADIR (FR) | 1996-12-18 | — | — | EP | disclosed |
| US-5472979-A | Antithrombotics | ADIR ET COMPAGNIE (FR) | 1995-12-05 | — | — | US | disclosed |
| EP-0648741-A1 | 1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents | ADIR ET COMPAGNIE (FR) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238785-A1 | Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders | TBXA2R, PTAFR, PTGIR | TBXA2R 1/4885TBXAS1 5/4885HDAC8 4232/4885 |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | SERPINC1, F2, TFPI | TBXA2R 37/4885TBXAS1 97/4885HDAC8 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.